This is a FIH Phase 1, non-comparative, open-label, basket-design study. The study will consist of 2 cohorts:~Solid tumours cohort~Haematologic malignancies cohort:~Subjects must fulfill entry criteria and have relapsed or refractory advanced malignancy for which no standard therapy exists.~An Data Safety Monitoring Committee (DSMB) will provide oversight of the study and will monitor safety on a regular basis throughout the study to make recommendations on any modifications.~The study will be comprised of 3 periods. Screening, Treatment and Follow-up.~All eligible subjects will receive minimally 3 weekly dosing of SUPLEXA. Subjects will be monitored closely at the clinic after each weekly infusion.~After completion of the first 3 weekly SUPLEXA the treatment period of SUPLEXA may be extended to every 2 weeks until all SUPLEXA is depleted.
This Phase 1, first-in-human (FIH), open-label study is designed to assess the safety, tolerability, and preliminary clinical efficacy of repeated intravenous (IV) infusions of SUPLEXA monotherapy in subjects with measurable metastatic solid tumours and haematologic malignancies